Dissemin is shutting down on January 1st, 2025

Published in

Springer Nature [academic journals on nature.com], Signal Transduction and Targeted Therapy, 1(4), 2019

DOI: 10.1038/s41392-019-0036-y

Links

Tools

Export citation

Search in Google Scholar

Targeting growth hormone function: strategies and therapeutic applications

Journal article published in 2019 by Man Lu, Jack U. Flanagan, Ries J. Langley ORCID, Michael P. Hay ORCID, Jo K. Perry ORCID
This paper is made freely available by the publisher.
This paper is made freely available by the publisher.

Full text: Download

Green circle
Preprint: archiving allowed
Red circle
Postprint: archiving forbidden
Green circle
Published version: archiving allowed
Data provided by SHERPA/RoMEO

Abstract

AbstractHuman growth hormone (GH) is a classical pituitary endocrine hormone that is essential for normal postnatal growth and has pleiotropic effects across multiple physiological systems. GH is also expressed in extrapituitary tissues and has localized autocrine/paracrine effects at these sites. In adults, hypersecretion of GH causes acromegaly, and strategies that block the release of GH or that inhibit GH receptor (GHR) activation are the primary forms of medical therapy for this disease. Overproduction of GH has also been linked to cancer and the microvascular complications that are associated with diabetes. However, studies to investigate the therapeutic potential of GHR antagonism in these diseases have been limited, most likely due to difficulty in accessing therapeutic tools to study the pharmacology of the receptor in vivo. This review will discuss current and emerging strategies for antagonizing GH function and the potential disease indications.